ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: SHP2 has been reported to mediate transformation of cells, and modulate MAPK and signal transducer and activator of transcription 3/5 (STAT3/5), signalling downstream of the breakpoint cluster region (BCR)-Abl fusion protein, which occurs frequently in chronic myelogenous leukaemia (CML) as a result of a chromosomal translocation event [22–28].